Invasive Serotype 35B Pneumococci Including an Expanding Serotype Switch Lineage, United States, 2015-2016
- PMID: 28516866
- PMCID: PMC5443455
- DOI: 10.3201/eid2306.170071
Invasive Serotype 35B Pneumococci Including an Expanding Serotype Switch Lineage, United States, 2015-2016
Erratum in
-
Correction: Vol. 23, No. 6.Emerg Infect Dis. 2017 Oct;23(10):1762. doi: 10.3201/eid2310.C12310. Emerg Infect Dis. 2017. PMID: 31305614 Free PMC article.
Abstract
We used whole-genome sequencing to characterize 199 nonvaccine serotype 35B pneumococcal strains that caused invasive pneumococcal disease (IPD) in the United States during 2015-2016 and related these findings to previous serotype 35B IPD data obtained by Active Bacterial Core surveillance. Penicillin-nonsusceptible 35B IPD increased during post-pneumococcal 7-valent conjugate vaccine years (2001-2009) and increased further after implementation of pneumococcal 13-valent conjugate vaccine in 2010. This increase was caused primarily by the 35B/sequence type (ST) 558 lineage. 35B/ST558 and vaccine serotype 9V/ST156 lineages were implicated as cps35B donor and recipient, respectively, for a single capsular switch event that generated emergent 35B/ST156 progeny in 6 states during 2015-2016. Three additional capsular switch 35B variants were identified, 2 of which also involved 35B/ST558 as cps35B donor. Spread of 35B/ST156 is of concern in view of past global predominance of pathogenic ST156 vaccine serotype strains. Protection against serotype 35B should be considered in next-generation pneumococcal vaccines.
Keywords: United States; bacteria; invasive pneumococcal disease; penicillin-binding protein types; pneumococcal 13-valent conjugate vaccine; pneumococcal 7-valent conjugate vaccine; pneumococcal conjugate; pneumococci; recombination; respiratory infections; serotype 35B; serotype expansion; serotype switch; surveillance; switch lineage; vaccines.
Figures



Comment in
-
Invasive Serotype 35B Pneumococci Including an Expanding Serotype Switch Lineage.Emerg Infect Dis. 2018 Feb;24(2):405. doi: 10.3201/eid2402.170982. Emerg Infect Dis. 2018. PMID: 29350161 Free PMC article. No abstract available.
References
-
- Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–9. 10.1016/S1473-3099(14)71081-3 - DOI - PMC - PubMed
-
- Beall B, McEllistrem MC, Gertz RE Jr, Boxrud DJ, Besser JM, Harrison LH, et al. ; Active Bacterial Core Surveillance/Emerging Infections Program Network. Emergence of a novel penicillin-nonsusceptible, invasive serotype 35B clone of Streptococcus pneumoniae within the United States. J Infect Dis. 2002;186:118–22. 10.1086/341072 - DOI - PubMed
-
- Sharma D, Baughman W, Holst A, Thomas S, Jackson D, da Gloria Carvalho M, et al. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Pediatr Infect Dis J. 2013;32:e45–53. 10.1097/INF.0b013e3182788fdd - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous